Defibrillation thresholds in hypertrophic cardiomyopathy

Area of Science:

• Cardiology
• Electrophysiology
• Medical Devices

Background:

• Defibrillation threshold (DFT) testing ensures safety for terminating ventricular arrhythmias.
• Left ventricular mass is a known predictor of high DFTs.
• Hypertrophic cardiomyopathy (HCM) patients are presumed at risk for increased defibrillation energy needs, but data are limited.

Purpose of the Study:

• To assess DFTs in patients with HCM.
• To identify clinical predictors of elevated DFTs in HCM patients.

Main Methods:

• A uniform modified step-down DFT testing protocol was used.
• Eighty-nine HCM patients and 600 control cardiomyopathy patients were studied.
• DFT was compared between groups, and predictors of elevated DFT were analyzed in the HCM cohort.

Main Results:

• No significant difference in DFT was observed between HCM and control groups (10.4 ± 5.8 J vs 11.2 ± 5.6 J).
• Clinical factors like ejection fraction, septal thickness, ventricular mass, and QRS duration did not predict elevated DFT in HCM patients.
• Only 3.4% of HCM patients exhibited a DFT greater than 20 J.

Conclusions:

• HCM patients do not demonstrate elevated DFTs compared to typical populations undergoing implantable cardioverter-defibrillator (ICD) implantation.
• Routine use of high-energy ICD devices or complex lead systems is not typically required for HCM patients.
• These findings support a standardized approach to ICD selection in HCM patients based on current evidence.